Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NV:yXHBRS2WubDDWbYFjcWyrdImgRZN{[Xl? NGPrTXExNTBwNTFOwG0> MWCyOEBp NV7UfWx{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= NVvZT4lJOjV4NkO3Olk>
HepG2-HBV1.1 M1PNTWFxd3C2b4Ppd{BCe3OjeR?= MmrSNE0xNjVizszN MknKNlQhcA>? M4PCPYlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= Mly1NlU3PjN5Nkm=
HepG2.2.15 M4O4VGZ2dmO2aX;uJGF{e2G7 MlrnNE4yKM7:TR?= NUHD[5R4OjRiaB?= NUfIcpVseHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v MWKyOVY3Ozd4OR?=
HepG2-HBV1.1 MnvUSpVv[3Srb36gRZN{[Xl? NEL1[o8xNjFizszN MonvNlQhcA>? MVrwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= NFXNUmwzPTZ4M{e2PS=>
HepG2-HBV1.1 MVvGeY5kfGmxbjDBd5NigQ>? NWnNRVRoOC5zIN88US=> NHTmZ481QCCq MVzwdo9ud3SnczDj[YxtKGW6Y4LleIlwdiCxZjDo[ZBifGm2aYOgRkB3cXK3czDueYNt\W:lYYDzbYR{KGmwc4TlZYQhd2ZiaHXwZZRqfGm|IFKgeolzfXNiRHHu[UBx[XK2aXPs[ZM> MVqyOVY3Ozd4OR?=
HepG2-HBV1.1 NEjSNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSwMlEh|ryP NYq5R24xOS13IHS= Mnq2bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= NF\0[2wzPTZ4M{e2PS=>
HepG2-HBV1.1 M3;5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzJd2wyOC5zIN88US=> NFX1TnIyNTViZB?= M2fHVYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= NWXCZVR4OjV4NkO3Olk>
HepG2-HBV1.1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\lZmcxNjFizszN NIPwdpYyOi15MjDo MU\pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W= NEi2N4QzPTZ4M{e2PS=>
HepG2-HBV1.1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HLU|AvOSEQvF2= MV:xNk04OiCq NXX2ellCcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm NYX2[YJKOjV4NkO3Olk>
Raji MWPGeY5kfGmxbjDBd5NigQ>? NFrqfFkxNjYEoN88US=> MknxO|IhcA>? MoLqZYJwdGm|aHXzJIF2fG:yaHHnfeKh NH61d24zPTR2NkO3Oy=>
SK-MEL-28  MmXWSpVv[3Srb36gRZN{[Xl? MYizNEBvVQ>? NGTrT4Q3KGh? M3KxOolv\HWlZYOgS|LjiJOPIHPlcIwu[3mlbHWgZZJz\XO2 NXXZTWhKOjV|MUOwNVA>
H157 M4rn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W2dWlEPTB;MT6wN{DDuSByLkC0JI1qfTKP MXKyOVI2PzlzMR?=
Jurkat NXPId5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3frZ|EuOyCwTR?= NFq0W4w1QMLiaB?= MXHEUXNQ NIPmUYJl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 NH33PWkzPTF3NkG0Oi=>
CEM MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml31NU0{KG6P MWK0POKhcA>? M{C1NWROW09? NHKxeZNl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 Mk\oNlUyPTZzNE[=
P12 NFrRbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyxMVMhdk1? NIj3RXc1QMLiaB?= NHTMcYJFVVOR NGfGUpRl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 MmmxNlUyPTZzNE[=
KB M3TFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;NZ5c3UUN3ME2wMlAxPDliwsGgNE4xODBzIN88US=> MmniNlUxPTh3Mk[=
KBv200 (ABCB1) NILme4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrnWWtKSzVyPUCuN|Q3OiEEsTCwMlAxPjZizszN Ml3INlUxPTh3Mk[=
SUDHL6  NIDWOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDDVJky6oDLzszN MYq0PE84OiCq NVfDd|FocW6qaXLpeJMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M2rkZ|I1QTZzNkC0
SUDHL6  MXTGeY5kfGmxbjDBd5NigQ>? NWXEbGg3OeLCid88US=> NWXvSo42PzJiaB?= NX3ofoJScW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI91cWNibX;ydIhwdG:peTDjbIFv\2W|IHPveJJme3SnZDD3bZRpKEKFTEGxRUB{cVKQQR?= MYCyOFk3OTZyNB?=
HCT-116 NYS5cJBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X3fWdKPTB;NTDuUS=> M1[5ZlI1QTJ5OEW3
SKNBe2C M2fXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXkcI11UUN3ME2zNk45yrF2LkCgcm0> NYn2eo96OjR7MkG5NlA>
IGNR91 M37PRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPCTWM2OD1{ND6zxtEyNjdibl2= M374NFI1QTJzOUKw
SKNAS MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj1PGVKSzVyPUGuOeKyOC5{IH7N MkjlNlQ6OjF7MkC=
LAN1 NVLPdHFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jBeWlEPTB;Mj6zxtExNjJibl2= Mnu1NlQ6OjF7MkC=
SHSY5Y NVHFZlNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRThwMtMxNE43KG6P MUKyOFkzOTl{MB?=
A549-WT NXOyeldDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;r[FFKSzVyPUG5MlQ{PyEEsTCwMlU6PCBibl2= MXWyOFg2QDh{Nx?=
A549-R MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1? MWGyOFg2QDh{Nx?=
MCF-7-WT MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHmRo4{UUN3ME2xO{44PTJiwsGgNE4zOThiIH7N MXGyOFg2QDh{Nx?=
MCF-7-R Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjPbHlKSzVyPUWuOVM6KMLzIECuNVQ1KCCwTR?= M{TSNVI1QDV6OEK3
A549-R M1vrXGN6fG:2b4jpZ4l1gSCDc4PhfS=> Mn;0TWM2OD1zMj6xO|ghyrFiMD6zN|Mhdk1? M1TCVlI1QDV6OEK3
MCF-7-R MmH0R5l1d3SxeHnjbZR6KEG|c3H5 M3XNTmlEPTB;NT61N|khyrFiMD6xOFQhdk1? M3fo[FI1QDV6OEK3
SW620 NITyZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfXO5FwUUN3ME23MlgxKMLzIECuNFghdk1? NFLYRoQzPDd{NkezPS=>
SW620/AD300 NFjQRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTlyOT62NEDDuSB6LkmxJI5O NHTYd44zPDd{NkezPS=>
HEK293/pcDNA3.1 M17GSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjpcWNKSzVyPUGuOFUhyrFiMD6yNEBvVQ>? MVmyOFczPjd|OR?=
HEK293/ABCC1 NEHMOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfESVRKSzVyPUG5MlI6KMLzIEKuNFghdk1? MVGyOFczPjd|OR?=
TCC MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofqNlQhcA>? MY\JR|UxRTdyIH7N M3PVZlI1PzF4OUS0
TCC NGXYbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PyWFQ5KGh? NGLIbZFKSzVyPUWwJI5O M{fJ[FI1PzF4OUS0
HepG2/ADM NY\6e3FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmyTWM2OD1{Lke4OlPDuTBwMkO3NUDPxE1? MknPNlQ4ODR3NU[=
HepG2 NWG5c5FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfYOVVKSzVyPUCuNFEyPcLzMD6wNFE4KM7:TR?= MWCyOFcxPDV3Nh?=
MCF-7/ADR M1LHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH36NmhKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?= NXHkWJNbOjR5MES1OVY>
MCF-7 NV2zc|h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInEd41KSzVyPUCuNFE2QcLzMD6wNFYzKM7:TR?= MXGyOFcxPDV3Nh?=
A-172  MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Ljd|AvOcLizszN MXyyOE84OiCq M3TEU4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> MkPnNlQ2OzB{M{W=
U-251MG NYDSZ41CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDId2QxNjIEoN88US=> MnvvNlQwPzJiaB?= MWfpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NFzmfFMzPDV|MEKzOS=>
DLD-1 NFjkfIhHfW6ldHnvckBCe3OjeR?= MYGxNFAhdk1? Mmm5OFghcA>? MnnOdJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh NXTY[FhxOjR2MEO0OVM>
CCD18Co MVvGeY5kfGmxbjDBd5NigQ>? NFHKTZAyODBibl2= MmHFOFghcA>? NYPV[4dZeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi NUPkbI5JOjR2MEO0OVM>
DLD-1 MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXUNE0yODByIH7N MWe0PEBp NWHNPVBRcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M4e0dVI1PDB|NEWz
CCD18Co NH3j[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKwMVExODBibl2= NIfFdpE1QCCq MYXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NVvtUnc4OjR2MEO0OVM>
HepG2 NH3KNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\xcnMzPCCq MnHBTWM2OD13Mj615qCK|ryP MnPONlQ{PDF4OEi=
HEK293/pcDNA3.1 M3ryfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULyV5prUUN3ME2wMlAxPMLzMD6wNFA{KM7:TR?= M3frSFI1Ojh2N{iz
HEK293/MRP1 NUDFN|BFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGqyT5lKSzVyPUCuNFU2yrFyLkCxNlAh|ryP M4CzR|I1Ojh2N{iz
Ramos NWfLbJhZSXCxcITvd4l{KEG|c3H5 MmjrNwKBkc7:TR?= MVW0PEBp NV\1c|RUcW6mdXPld{A{PC54JdMxNU46OiViYYDvdJRwe2m| NGe1PYYzPDJ3NkS5NS=>
NCI-H1299/pcDNA3 NVfvVmZ5S2WubDDWbYFjcWyrdImgRZN{[Xl? M2n5fFAuOjBibl2= MWG5OkBp Ml\PbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MXSyOFE4PzBzMh?=
H1299/ICAM-3 M3;SfmNmdGxiVnnhZoltcXS7IFHzd4F6 Ml7nNE0zOCCwTR?= NIm1e|k6PiCq M4rONIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NGPCfJUzPDF5N{CxNi=>
NCI-H1299/pcDNA3 MmT3SpVv[3Srb36gRZN{[Xl? M3:4RlEwPS9zMD:yNOKhdk1? MXG5OkBp M1nwc4lv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA> NIfRVFgzPDF5N{CxNi=>
H1299/ICAM-3 M1v4UWZ2dmO2aX;uJGF{e2G7 MkPjNU82NzFyL{KwxsBvVQ>? MVK5OkBp MY\pcoR2[2W|IHPs[YF3[WenIH;mJINie3Cjc3XzMVMtKDhuIEmsJIFv\CCSQWLQ M{HXR|I1OTd5MEGy
W1 NFiz[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rh[WlEPTB;MD6wNFMzKM7:TR?= MmnXNlQyPDBzN{[=
W1VR M1HP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jGZmlEPTB;MD6wOVYh|ryP NEXScHozPDF2MEG3Oi=>
K562 NU\1b3NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEOyJOKyKDBwMECxJEDPxE1? NWToNWx[OjRzM{W5N|c>
K562/ADR Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH74RYFKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?= NHTBdHkzPDF|NUmzOy=>
K562 MmXsRZBweHSxc3nzJGF{e2G7 MlfuNE4{KM7:TR?= NUPVZXJwOjRiaB?= NV\JVnpzcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= NYK0[5lVOjRzM{W5N|c>
K562/ADR M1XIUmFxd3C2b4Ppd{BCe3OjeR?= MX:zJO69VQ>? Mk\uNlQhcA>? Ml;IbY5lfWOnczDhdI9xfG:|aYO= MXiyOFE{PTl|Nx?=
A549 NGe3dWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMUCgxtEhOC5yMzFOwG0> M2W3O|I{QTdzMEe1
K562 M2m5bmNmdGxiVnnhZoltcXS7IFHzd4F6 M4joUVMvPzYkgKO2NOKhdk1? Mn\NO|LDqGkEoB?= NHfyTXdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MUGyN|g4PzJ{Mx?=
lucena NX\WSHdiS2WubDDWbYFjcWyrdImgRZN{[Xl? NXXmXnpxOy55NfMAl|YxyqCwTR?= MlG2O|LDqGkEoB?= NIiw[lFvdyCnZn\lZ5Q> NGrJNWMzOzh5N{KyNy=>
FEPS M{X5ZmNmdGxiVnnhZoltcXS7IFHzd4F6 MmP6N{44PeLCk{[wxsBvVQ>? NYPtPWVzPzMEoHlCpC=> M2LScY5wKGWoZnXjeC=> MUiyN|g4PzJ{Mx?=
A2780 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwNTDtUS=> M3HOelI{QDJ7MkCz
ACHN MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHweJJEUUN3MEywMlEhdU1? MlHjNlM5Ojl{MEO=
U-937 M2C1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHtcZdsUUN3MEyzOEBvVQ>? MoTrNlM5Ojl{MEO=
Jurkat MnHmRZBweHSxc3nzJGF{e2G7 M1XGclXDqM7:Zz;tcOKh Ml3tNlQhcA>? MnzVbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MmnDNlM5OTB2MEm=
Jurkat MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHyOeKh|rypL33sxsA> MYGyOEBp NUHUdIM2[XK{ZYP0JGp2emujdDDj[YxteyCrbjDHNk9OKHCqYYPl MnHsNlM5OTB2MEm=
Hep-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTiTWM2OD1yLkC0xtExNjBzIN88US=> NYfxb2dvOjN5OEC0NlQ>
Hep-2/v Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTtb4IzUUN3ME2xMljDuTBwMkCg{txO NXHvZoxPOjN5OEC0NlQ>
SGC-7901 NYjFUIxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrjN2gxNTFyIN88[{9udA>? MoDFNlQwPDhxN{KgbC=> MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NGrYe5gzOzd2M{W3Ni=>
SGC-7901/VCR NIDwNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfWNE0yOCEQvHevcYw> M{jv[VI1NzR6L{eyJIg> MV;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MWOyN|c1OzV5Mh?=
SGC-7901 NUTnXVZHSXCxcITvd4l{KEG|c3H5 M{L4V4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MWSyN|c1OzV5Mh?=
SGC-7901/VCR NHrIe29CeG:ydH;zbZMhSXO|YYm= NHW3cldqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 MknoNlM4PDN3N{K=
KB-3-1 NW\hSppzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLjTWM2OD1zLk[2JOKyKDBwMU[yJO69VQ>? NYLMe2puOjN4N{O0OFU>
KB-C2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJyMj61OkDDuSB2Mj60PFEh|ryP MoHWNlM3PzN2NEW=
KB-3-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPBTWM2OD1zLkK2JOKyKDBwMEK3JO69VQ>? M4mwZ|I{Pjd|NES1
KB-V1 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGWyRWpKSzVyPUKwPE45PSEEsTCyNE41KM7:TR?= M4\Ce|I{Pjd|NES1
HEK293/pcDNA3.1 NH;hWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLV[ZZnUUN3ME2yOE4yKMLzIECuNlA1KM7:TR?= NHr1N4gzOzZ5M{S0OS=>
HEK293/ABCB1 NHXtNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN3MUKuPEDDuSB|N{iuN|kyKM7:TR?= NITtdXAzOzZ5M{S0OS=>
A549/EGFP  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPwXXIxNjBzLUGwNFAh|ryP M3;De2lEPTB;OE[uO{DDuSB{OT6xJO69VQ>? M3LITVI{PjN2Mkiy
A549/Slug MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm2NE4xOS1zMECwJO69VQ>? MXnJR|UxRTlwNzFCtUA{NjFizszN NIj0UIszOzZ|NEK4Ni=>
JFCR39  NH31dIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxJOK2VQ>? MYqyOEBp MUDEUXNQ NE\YVlRu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy| NXLKV4RNOjN3OUiyO|Y>
A549 NVPsfWVUTnWwY4Tpc44hSXO|YYm= MYGxNFAhdk1? NUXNeGhmOTZiaB?= M2nCUWROW09? MnrlcIVi\HNidH:gZUBtd3O|IH;mJI1q[3KxdIXieYxmew>? NWPyPIlWOjN3OUiyO|Y>
SGC7901 NIm0OodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLTTWM2OD1zLkK25qCKyrIkgJmwMlEyKM7:Zz;tcC=> MoW3NlM2PjR2OEK=
SGC7901/LV-NC M2XLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELkTIlKSzVyPUGuO|fjiIoEsfMAjVAvOTZizsznM41t MXSyN|U3PDR6Mh?=
SGC7901/LV-SGO1 NYXVcWNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknGTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=> M1XyNlI{PTZ2NEiy
SGC7901/VCR MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG0R|B[UUN3M{2yNE42O+LCidMx5qCKOS57NjFOwIcwdWx? NIfoeoUzOzV4NES4Ni=>
SGC7901/VCR-NC M1fRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK0UIJnUUN3ME2xPU45PuLCidMx5qCKOi5yMTFOwIcwdWx? MXuyN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 NF\jdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTZwMUlihKnDueLCiUGuNFMh|rypL33s MU[yN|U3PDR6Mh?=
SGC7901/ADR Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHzUmFZUUN3ME23Mlg26oDLwsJihKkxNjZ2IN88[{9udA>? M2HRc|I{PTZ2NEiy
SGC7901/ADR-NC NX;RS4ttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rSXmlEPTB;OD65N-KBkcLz4pEJNE43QCEQvHevcYw> MYeyN|U3PDR6Mh?=
SGC7901/ADR-si-SGO1 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17Oc2lEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw> M{XFOlI{PTZ2NEiy
SH-SY5Y  NX;5WGVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GwSFAvODBzLUGwJO69VQ>? NEHhUGozPCCq M3jnUGlEPTB;MD6xNVPDuTBwMEGyJO69VQ>? NHK3TZAzOzF{OUC2OS=>
SH-SY5Y  M3z0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPIe3pyOC5yMEGtNVAh|ryP NHXYdG81QCCq Mlr0TWM2OD1yLkC3POKyOC5yMEmg{txO NGnBPXkzOzF{OUC2OS=>
SH-SY5Y  NHS1TYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfsNE4xODFvMUCg{txO NWH4ZWFvPzJiaB?= NWTNOpVUUUN3ME2wMlA2OcLzMD6wNFgh|ryP MY[yN|EzQTB4NR?=
SH-SY5Y MWrBdI9xfG:|aYOgRZN{[Xl? NX73OW4{OC5zIN88US=> M4jjXVAuOjRiaB?= NVnVR|NxcW6mdXPld{BieG:ydH;zbZMhd2ZiU1itV3k2YSClZXzsd{Bnd2yub4fpcoch[2WubDDjfYNt\SCjcoLld5Qh[XRidHjlJGczN01icHjhd4U> MWiyN|EzQTB4NR?=
SH-SY5Y NGHZRoVCeG:ydH;zbZMhSXO|YYm= M1\le|AvOSEQvF2= NXfHXYFGOC1{NDDo NFrIPFZqdmS3Y3XzJI1qfG:2aXOgZZJz\XO2wrC= NIDGcYszOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023358 Not yet recruiting Peripheral T Cell Lymphoma Nanfang Hospital of Southern Medical University February 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03003520 Recruiting Lymphoma, Large B-Cell, Diffuse Celgene February 2017 Phase 2
NCT03018626 Not yet recruiting Lymphoma, Large B-Cell, Diffuse Nanfang Hospital of Southern Medical University February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID